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This Month in the Journal
Familial Partial Lipodystrophy (Dunnigan Variety), by
Speckman et al. (p. 1192); and Mutations in the
LMNA Gene, by di Barletta et al. (p. 1407)
Once known only to play a role in the maintenance of
nuclear structure, the nuclear lamina has lately become
a larger field of study. Mutations in the proteins that
make up the bulk of the nuclear lamina, the lamins, are
involved in Emery-Dreifuss muscular dystrophy (EMD;
see the Bonne et al. [1999] entry in the References lists
of both articles), Dunnigan-type familial partial lipo-
dystrophy (FPLD; see the Cao and Hegele [2000] entry
in the References lists of both articles), and dilated car-
diomyopathy and conduction disease (DCM; see the Fat-
kin et al. [1999] entry in the References lists of both
articles). The lamins are a family of highly conserved
proteins that form a layer on the nucleoplasmic side of
the inner nuclear membrane. They dimerize into coiled
coils through a central rod domain and interact with
chromatin and integral proteins of the nuclear
membrane. Hyperphosphorylation of the lamins is cor-
related with dissolution of the lamina during mitosis, a
process that is necessary but not sufficient for break-
down of the nuclear envelope. Lamins A and C are pro-
duced through alternative splicing of the message from
LMNA, the gene involved in at least some forms of
EMD, FPLD, and DCM. Production of lamins A and C
is developmentally regulated; although both proteins are
eventually found in most tissues, expression is stage spe-
cific and tissue specific.
EMD is a disorder characterized by early-onset con-
tractures, progressive weakness in humeroperonealmus-
cles, and cardiomyopathy with conduction block. There
are X-linked, autosomal dominant, and autosomal re-
cessive forms of this disease. The X-linked form of EMD
is caused by mutations in the gene for emerin (see the
Bione et al. [1994] entry in the References list of the di
Barletta et al. article), a protein that associates with the
nuclear rim and that colocalizes with lamins A and C.
The autosomal dominant form of EMD results from
mutations in LMNA (see the Bonne et al. [1999] entry
in the References lists of both articles). di Barletta et al.
have studied several patients with EMD and have found
LMNA mutations in all of them. Despite having mu-
tations in the same gene, these patients presented with
a range of clinical phenotypes, from a slight increase in
creatine kinase levels to a severe muscular dystrophy.
The inheritance pattern of the disease also differed be-
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tween families, with some exhibiting autosomal recessive
EMD and others exhibiting autosomal dominant forms
of EMD with reduced penetrance. Thus, mutations in
LMNA lead to several forms of EMD, but the distri-
bution of the mutations along LMNA does not explain
the differences in either phenotype or inheritance
pattern.
FPLD, another disease associated with mutations in
LMNA (see the Cao and Hegele [2000] entry, in the
References lists of both articles, and the Shackleton et
al. [2000] entry, in the References list of the Speckman
et al. article), is an autosomal dominant disorder in
which there is a loss of subcutaneous adipose tissue in
the trunk and extremities. Speckman et al. have per-
formed mutational analysis on 15 families with FPLD
and have found that 14 had missense mutations in
LMNA, 12 of these at residue R482. The remaining
mutations were a G465D mutation and an R582H
mutation, thereby localizing all known FPLD-causing
mutations to the globular C-terminal domain of lamin
A/C.
It has been proposed that the location of mutations
in LMNA determines the resulting phenotype. In gen-
eral, mutations associated with DCM are found in the
beginning of the rod domain of lamin A/C; those as-
sociated with EMD are found from the C-terminal end
of the rod domain into the C-terminal globular domain
(although a severely truncated form of the protein leads
to EMD); and those leading to FPLD are found only in
the C-terminal globular domain. However, data pre-
sented in this issue indicate that the causative mutations
for EMD, DCM, and FPLD are interspersed along
LMNA and that none of the lamin A/C domains is spe-
cifically associated with any one disorder.
DCM and EMD both affect muscle tissue and may be
part of a phenotypic spectrum; some patients with DCM
have partial skeletal-muscle involvement, and some pa-
tients with EMD have cardiomyopathy. The relationship
between these muscular disorders and FPLD, a disease
of adipose tissue, is not clear. The varied phenotypic
effects of LMNA mutations may be due to the tissue-
specific and developmentally regulated expression levels
and the spatial arrangement of the lamins within cells.
Furthermore, mutations may disrupt tissue- or cell-
specific interactions of LMNA, leading to localized de-
fects. Additional mutational analyses of LMNA will be
required in order to determine how mutations that are
closely apposed lead to very different disorders.
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Effects of ATP7A Splice-Site Mutations, by Møller et
al. (p. 1211)
Mutations in ATP7A lead to one of two copper-
deficiency disorders: Menkes disease (MD) or the milder
form, occipital horn syndrome (OHS). ATP7A encodes
a copper-transporting P-type ATPase that moves copper
through and out of cells. Mutations in ATP7A—and the
resulting copper-transport deficiency—yield markedly
elevated copper concentrations in the fibroblasts of pa-
tients with either disorder, as well as decreased copper
levels in their sera and hair. Malfunction of copper-
requiring enzymes apparently leads to the clinical man-
ifestations of MD and OHS—namely, connective-tissue
abnormalities and neurological degeneration. However,
the explanation for the more severe MD phenotype has
so far not been clear. Møller et al. have examined this
problem through genotype-phenotype correlations for
the ATP7A locus, using patients with similar splice-site
mutations but different clinical outcomes. These pa-
tients, one with OHS and two with MD, all have mu-
tations that are found at the same splice donor site of
ATP7A and that lead to skipping of exon 6. By two
different quantitative PCR methods, a small amount of
correctly spliced ATP7A transcript (2%–5% control)
was found in the patient with OHS. Although each pa-
tient with MD had ATP7A transcripts that were ap-
proximately the right length, the use of cryptic splice
sites in both patients with MD was predicted to yield a
severely truncated and completely nonfunctional pro-
tein. These results suggest that a very small amount of
full-length ATP7A transcript—and the subsequent pro-
duction of the encoded copper transporter—is sufficient
to permit development of OHS, rather than the more
severe MD phenotype.
Genetic Effects on Iron Stores, by Whitfield et al. (p.
1246)
Hemochromatosis is a common, autosomal recessive dis-
order characterized by excessive iron accumulation that
can damage the heart, liver, pancreas, and pituitary
gland. Periodic removal of blood can lower iron levels
and prevent tissue damage, but early identification of
affected individuals is essential for this treatment to be
effective. The most common mutation in the gene for
hemochromatosis, HFE, is C282Y. This tyrosine sub-
stitution abrogates binding of the HFE protein to beta-
2-microglobulin and disrupts the transport of HFE to
the cell surface. There, HFE would normally associate
with transferrin receptor and modulate the uptake of
transferrin-bound iron by the intestinal crypt. The role
that another commonHFE polymorphism, H63D, plays
in hemochromatosis is less clear. Whitfield et al. have
assessed the effects of the C282Y and H63D HFE gen-
otypes, as well as age, sex, and ethnicity, on iron storage
and metabolism. Although neither simple heterozygotes
nor C282Y/H63D compound heterozygotes are likely to
be affected by hemochromatosis, C282Y and H63D in-
fluence iron stores in the heterozygous state. However,
their effect on iron stores accounts for only a small per-
centage of the phenotypic variance, indicating that there
are other significant, but unidentified, genetic influences
on iron stores. In response to the HFE polymorphisms,
serum iron and transferrin saturation are altered to a
greater extent than are ferritin levels, a result that raises
doubt as to which measurement is the best index of body
iron stores when one is assessing risk of iron overload
or deficiency.
Surnames and the Y Chromosome, by Sykes and Irven
(p. 1417)
For several hundred years, children have been given their
father’s surname, as a matter of tradition. Along with a
last name, sons also inherit a Y chromosome. Since both
surname and Y-chromosome haplotype should be in-
herited together, Sykes and Irven examined the corre-
spondence between the two, using a sample of British
individuals with the surname “Sykes.”A single haplotype
at the nonrecombining segment of the Y chromosome
was carried by 43.8% of the Sykes sample, and this
haplotype was not found in any of the control individ-
uals. For this haplotype to occur with such prevalence,
a single, patrilineal ancestor must have founded the
Sykes sample, with little genetic divergence occurring
since the lineage was founded. Sykes individuals without
the common haplotype probably inherited the name be-
cause of nonpaternity, an event that was estimated to
occur at an average rate of 1.3%/generation.
Chromosome 3 Cataract and BFSP2, by Conley et al.
(p. 1426); and Cataract Associated with BFSP2
Mutation, by Jakobs et al. (p. 1432)
Autosomal dominant congenital cataracts (ADCC) are
a genetically heterogeneous group of disorders. Identi-
fied in the 15 genetic regions that have shown linkage
to ADCC are several causative genes, including those for
various crystallin proteins, connexins 46 and 50, gap-
junction proteins, and a homeobox protein. Another
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possible ADCC locus is found on chromosome 3q21.2-
q22.3, and this region includes the gene for beaded fil-
ament structural protein 2 (BFSP2). Expression of BFSP2
is restricted to fiber cells of the ocular lens, making it a
candidate gene for ADCC. Two articles in this issue of
the Journal propose that mutations in BFSP2 lead to
ADCC, making it the first cytoskeletal protein to be
associated with cataracts. Conley et al. found an R287W
mutation that alters a highly conserved positive charge
in BFSP2. The DE233 BFSP2 mutation, identified by Ja-
kobs et al., breaks a repeated, conserved pattern that is
required for coiled-coil dimer formation. Although the
function of BFSP2 is not yet known, both mutations are
predicted to alter intermediate filament assembly in the
ocular lens. Despite these predictions, the mutations dif-
fer in the age at onset of clinical symptoms. Many of
the family members with the DE233 mutation developed
cataracts in early childhood and had corrective surgery
at age 3–5 years. In contrast, the onset of clinical symp-
toms in the family with the R287W mutation occurred
at age 8–25 years.
May-Hegglin Anomaly Maps to 22q12.3-13.1, by
Martignetti et al. (p. 1449)
In this issue of the Journal, we are proud to present one
of the first studies to use the chromosome 22 sequence
to localize a genetic region of interest. Martignetti et al.
have studied a large family affected by May-Hegglin
anomaly (MHA), a platelet disorder that can lead to
bleeding episodes. The gene for MHA was mapped to
a 6.6-cM region on chromosome 22q. Using the newly
published chromosome 22 sequence, this group was able
to order the genetic markers in the region and to deter-
mine the physical distance between the boundary mark-
ers. This analysis narrowed the region of interest to 700
kb and identified candidate-gene sequences within the
region. In addition to greatly narrowing the MHA re-
gion, these studies illustrate the direct application of the
Human Genome Project.
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